Morphologic Changes in the Gastric Mucosa of Rats and Dogs Treated with an Analog of Prostaglandin E 1

Abstract

American Cyanamid compound CL 115,574, a synthetic analog of prostaglandin E₁, is active orally in inhibiting gastric acid secretion and in protecting against gastric ulcers induced by stress, ethanol, and nonsteroidal anti-inflammatory drugs. CL 115,574 was administered to rats for 6 months and to dogs for 1 year. Diarrhea occurred in both species and transient hyperthermia was observed in dogs. In rats, the only gross finding related to treatment was limited to the gastric mucosa and consisted of a dose-related widening of the cuticular ridge in the mid (2 mg/kg/day) and high (20 mg/kg/day) dose groups. Microscopically, there was a proliferation of the cuticular ridge stratified squamous epithelium. Morphologic findings in the dogs showed a multifocal proliferation of the foveolar epithelium in the pyloric antrum. Neither species had atypical cellular changes associated with the proliferative process. Furthermore, the changes in the dog consisted of well differentiated cells and occurred without pseudostratification of cells and increased mitotic activity. The “pseudoproliferative” character of these changes may be the result of a prolonged life span of most cell types of the gastric mucosa. These tissue adaptations reflect a true manifestation of the cytoprotective effect of prostaglandin E₁ on the gastric mucosa.

References

1. Bennet A and Fleshler B (1970). Prostaglandins and the gastrointestinal tract. Gastroenterology 59: 790–800.

2. Bloom SR (1978). Gut Hormones. Churchill, Edinburg.

3. Borowska A , Mackowiak J , and Wisniewski K (1981). Prostaglandins (PGs) and peristalsis. Prostaglandins Med. 6: 13–16.

4. Bowen JC , Kuo YJ , Pawlik W , Williams D , Shanbour LL , and Jacobson ED (1975). Electrophysiological effects of burimamide and 16,16-dimethylprostaglandin E2, on the canine gastric mucosa. Gastroenterology 68: 1480–1484.

5. Chaudhury TK and Jacobson Ed (1978). Prostaglandin cytoprotection of the gastric mucosa. Gastroenterology 74: 58–63.

6. Classen M , Koch H , Buckhardt J , Topf G , and Demling L (1971). The effect of prostaglandin E1 on the pentagastrin-stimulated gastric secretion in man. Digestion 4: 333–334.

7. Delaney JP , Michel HM Bonsack ME , Eisenberg MM , and Dunn HH (1979). Adrenal corticosteroids cause gastrin cell hyperplasia. Gastroenterology 76: 913–916.

8. Enochs MR and Johnson LR (1976). Effect of hypophysectomy and growth hormone on serum and antral gastrin levels in the rat. Gastroenterology 70: 727–732.

9. Feldberg W and Saxena PN (1971). Fever produced by prostaglandin E1. J. Physiol. (Lond.) 217: 547–556.

10.

10. Feldberg W , Gupta KP , and Milton AS (1973). Effect of pyrogen and antipyretics on prostaglandin activity in cisternal C.S.F. of unanaesthetized cats. J. Physiol. (Lond.) 234: 279–303.

11.

11. Goldblatt MW (1933). A depressor substance in human seminal plasma. J. Soc. Chem. Ind. (Lond.) 52: 1056–1057.

12.

12. Iatropoulos MJ (1985). Morphology of the alimentary tract. In: Gastrointestinal Toxicity, KK Rozman , R Crampton , and O. Haenninen (eds). Elsevier Science Publisher, B.V. Amsterdam, Holland.

13.

13. McDonald C , Trier JS , and Everett B (1964). Cell proliferation and migration in the stomach, duodenum, and rectum of man. Gastroenterology 46: 405–417.

14.

14. Miller TA and Jacobson ED (1979). Gastrointestinal cytoprotection by prostaglandins. Gut. 20: 75–87.

15.

15. Milton AS and Wendlandt S (1971). Effects on body temperature of prostaglandins of the A, E, and F series on injection into the third ventricle of unanaesthetized cats and rabbits. J. Physiol. (Lond.) 218: 325–336.

16.

16. Newman A , DeMoraes-Filho PP , Philippakos D , and Misiewicz JJ (1975). The effect of intravenous infusions of prostaglandins E2 and F2α on human gastric function. Gut 16: 272–276.

17.

17. Reinhart WH , Mueller O , and Halter F (1983). Influence of long-term 16,16-dimethyl prostaglandin E2 treatment on the rat gastrointestinal mucosa. Gastroenterology 85: 1003–1010.

18.

18. Robert A (1976). Antisecretory, antiulcer, cytoprotective, and diarrheogenic properties of prostaglandins. Adv. Prostaglandin Thromboxane Res. 2: 507–520.

19.

19. Robert A (1983). Cytoprotection of the gastrointestinal mucosa. Adv. Intern. Med. 28: 325–338.

20.

20. Robert A , Nezamis JE , and Phillips JP (1967). Inhibition of gastric secretion by prostaglandins. Am. J. Dig. Dis. 12: 1073–1076.

21.

21. Robert A , Nezamis JE , and Phillips JP (1968). Effect of prostaglandin E1 on gastric secretion and ulcer formation in the rat. Gastroenterology 55: 481–487.

22.

22. Robert A , Nezamis JE , Lancaster C , and Hanchar AJ (1979). Cytoprotection by prostaglandins in rats. Gastroenterology 77: 433–443.

23.

23. Robert A , Hanchar AJ , Lancaster C , Nezamis JE , Culp JW , and Li LH (1980). Prevention of cellular shedding as a mechanism of gastric cytoprotection by prostaglandins. Gastroenterology 78: 1244.

24.

24. Ruppin H , Person B , Domschke W , and Robert A (1979). Zytoprotektive wirkungen von prostaglandin E2 auf die magenschleimhaut beim menschen. Dtsch. Med. Wochenschr. 104: 1457–1458.

25.

25. Ruppin H , Person B , Robert A , and Domschke W (1981). Gastric cytoprotection in man by prostaglandin E2. Scand. J. Gastroenterol. 16: 647–652.

26.

26. Snedecor GW (1956). Statistical Methods. The Iowa State College Press, Ames, Iowa, 5th Edition, Chapter 11.

27.

27. Von Euler US (1935). Uber die spezifsche bludrucksenkende substanz des menchlichen prostata- und samenblasensekretes. Klin. Wochenschr. 14: 1182–1183.

28.

28. Weisblat DI (1981). Prostaglandins: an overview. Conn. Med. 45: 144–147.

29.

29. Wilson DE , Phillips C , and Levine RA (1971). Inhibition of gastric secretion in man by prostaglandin A1. Gastroenterology 61: 201–206.

30.

30. Wissner A and Birnbaum JE (1980). Prostaglandins and congeners. 25. Inhibition of gastric acid secretion. Replacement of the carboxylate moiety of a prostaglandin with a hydroxymethylketo functional group. J. Med. Chem. 23: 715–717.